Artwork

Content provided by David Henry’s JCSO Podcast and David Henry. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by David Henry’s JCSO Podcast and David Henry or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

JCSO Podcast 6 Nov - Dec 2017

27:42
 
Share
 

Manage episode 197936907 series 1414118
Content provided by David Henry’s JCSO Podcast and David Henry. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by David Henry’s JCSO Podcast and David Henry or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
In the final JCSO podcast for 2017, Dr David Henry, the Editor-in-Chief, discusses a round-up by Dr Linda Bosserman of cancer care in 2017 and an accompanying article on the therapeutic implications of some of the year’s landmark approvals. Continuing with the theme of therapeutic advances, he also highlights a review of the expanding treatment options for diverse neuroendocrine tumors. Two articles, one on setting up systems to facilitate adoption of the oncology care model in the practice setting and another on the clinical presentation, diagnosis, and management of bronchopulmonary carcinoid, provide evidence-based information and guidelines for practice-based oncology care teams. Patient and survivor care are the focus of three original research reports in which authors report on supportive medications and interventions received by prostate cancer survivors (PiCTure study); differences in psychosocial stressors between black and white cancer patients; and the impact of combining human and online supportive resources for prostate cancer patients. Also discussed are case reports on metastatic eccrine carcinoma with stomach and pericardial involvement and on cold hemolytic anemia as a rare complication of influenza A, as well as the approvals of pembrolizumab for dMMR/MSI-H tumors and brigatinib for crizotinib-resistant, ALK-positive NSCLC patients.
  continue reading

12 episodes

Artwork
iconShare
 
Manage episode 197936907 series 1414118
Content provided by David Henry’s JCSO Podcast and David Henry. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by David Henry’s JCSO Podcast and David Henry or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
In the final JCSO podcast for 2017, Dr David Henry, the Editor-in-Chief, discusses a round-up by Dr Linda Bosserman of cancer care in 2017 and an accompanying article on the therapeutic implications of some of the year’s landmark approvals. Continuing with the theme of therapeutic advances, he also highlights a review of the expanding treatment options for diverse neuroendocrine tumors. Two articles, one on setting up systems to facilitate adoption of the oncology care model in the practice setting and another on the clinical presentation, diagnosis, and management of bronchopulmonary carcinoid, provide evidence-based information and guidelines for practice-based oncology care teams. Patient and survivor care are the focus of three original research reports in which authors report on supportive medications and interventions received by prostate cancer survivors (PiCTure study); differences in psychosocial stressors between black and white cancer patients; and the impact of combining human and online supportive resources for prostate cancer patients. Also discussed are case reports on metastatic eccrine carcinoma with stomach and pericardial involvement and on cold hemolytic anemia as a rare complication of influenza A, as well as the approvals of pembrolizumab for dMMR/MSI-H tumors and brigatinib for crizotinib-resistant, ALK-positive NSCLC patients.
  continue reading

12 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide